Kornimate/medical-research-clean huggingface dataset:
gene expression profiling in normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum

Conditions: Colorectal Cancer; Metastatic Cancer

Summary: rationale: studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer. purpose: this laboratory study is using gene expression profiling to evaluate normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum.

objectives: * evaluate gene expression profiles in normal and tumor tissue from patients with colon cancer metastatic to the liver, lungs, or peritoneum. * establish cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum. * determine the specific gene expression changes that result in the manifestation of the drug-resistant phenotype for each metastatic site. outline: this is a pilot study. tumor and normal tissue collected during surgery are analyzed for gene expression profiling by cdna microarray. tissue is also analyzed for thymidylate synthase (ts) gene expression by quantitative pcr and for protein expression by western blot. gene expression patterns are correlated with ts levels.

Eligibility criteria:
disease characteristics: * diagnosis of colon cancer metastatic to the liver, lungs, or peritoneum patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: stage iv colon cancer liver metastases lung metastases recurrent colon cancer
cest in low-grade glioma study

Conditions: Low-grade Glioma

Summary: low grade gliomas (lggs) are malignant, infiltrative and incurable brain tumours that typically present in the younger population. this project proposes to use non-contrast metabolic "saturation transfer" (st)-mri to evaluate lgg tumour progression and aims to predict early changes in lgg. early identification of lgg patients whose tumours will progress will permit early interventions. st-mri does not involve any intravenous injection of contrast and which acquires metabolic information not seen by standard mri.

please see trial details below:

Eligibility criteria:
inclusion criteria: 1. be at least 12 years of age; 2. diagnosed with: 1. cohort a (pre-surgical): suspected lgg (oligodendroglioma or astrocytoma), based on any combination of histological, molecular, radiological, and/or clinical findings; or 2. cohort b (post-surgical): idh1/2-mutant or idh-wildtype (wt) low-grade glioma candidate for observation 3. no contraindications to mri; 4. egfr \> 30 ml/min; 5. no prior chemotherapy or radiation therapy; 6. no need for upfront treatment (surgery, chemotherapy, and/or radiation therapy) 7. followed at either sunnybrook health sciences centre or at st michael's hospital exclusion criteria: 1. need for upfront post-surgical treatment with either chemotherapy and/or radiation therapy 2. pregnancy
changes in acid base status during high salt intake

Conditions: Low Grade Metabolic Acidosis

Summary: the study aimed to examine the effects of an alkalinisation of a nacl (sodium chloride, salt)-rich diet on acid base status, bone metabolism, protein turnover and other influenced physiological systems. due to increased urinary calcium excretion and bone resorption a high nacl-intake is considered as a risk factor for osteoporosis. on the contrary an alkaline diet is known to have a beneficial influence on bone metabolism. therefore the investigators hypothesized that an alkaline diet can reduce nacl-induced bone resorption. 8 healthy male volunteers took part in a stationary study carried out in the metabolic ward of the german aerospace center. the study consisted of 2 campaigns, each lasting 16 days. both campaigns were divided into 5 days of adaptation, 10 days of intervention and 1.5 days of stationary recovery. during the intervention period the volunteers diet was nacl-rich (7.7 mmol na/kg body weight/day) and supplemented in one campaign by 90 mmol potassium bicarbonate (khco3) in a randomized cross-over design. the other campaign served as control. bone metabolism was studied by bone formation markers in the fasting morning blood and 24h-urinary bone resorption markers. acid base status was assessed by blood gas analyses in the fasted and the postprandial state as well as urinary markers. protein turnover was studied with stable isotopes. further physiological systems like energy metabolism and the cardiovascular system are also under investigation.


Eligibility criteria:
inclusion criteria: * healthy males * 19 - 35 years * 65 - 85kg * 170 - 190 cm * successfully completed psychological and medical screening exclusion criteria: * athletes * smoking * drug- or alcohol abuse * hyperlipidemia * renal diseases * obesity * anemia * bone diseases * diabetes * rheumatism * blood donation within three month prior to study start * participation in another clinical investigation three month prior to study start
neuromuscular blockade comparison for gi-2 recovery after bowel resection

Conditions: Intestinal Disease

Summary: the purpose of this research study is to see the outcome of sugammadex versus neostigmine with glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (gi-2 recovery) following bowel resection surgery

neuromuscular blocking agents are essential during surgical procedures to paralyze the body to avoid unnecessary movement during surgery. there are various medications, such as sugammadex that are later used to reverse the effects of the neuromuscular blockade. the u.s. performs approximately 320,000 colectomies per year for benign and malignant conditions such as ulcerative colitis (uc). bowel resection surgery removes a portion of small or large intestine. currently, there is little available prospective outcomes data regarding the use of sugammadex versus neostigmine with glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (hour) to first bowel movement and tolerance for solid food (aka gi-2 recovery) following bowel resection surgery. the study team will be conducting a randomized triple-blind study (patient's assigned group is hidden from the patient, provider, and research team). randomization is created by using an electronic randomizer. upon consent, the patient's assignment (per the randomizer) will be submitted to the investigational drug service (ids) pharmacy by a department employee with no direct patient interaction.

Eligibility criteria:
inclusion criteria: * age 18 or older * laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission exclusion criteria: * allergy to rocuronium, vecuronium, or sugammadex * bowel resection surgery requiring an ostomy * no severe valvulopathy, no systolic heart failure with reduced ejection fraction (hfref), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality * no autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no copd with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin * creatinine clearance (crcl) of less than 30 * pregnancy * incapable of providing consent or understanding the research project

Keywords: laparoscopic bowel resection sugammadex neostigmine glycopyrrolate gi-2
observational cohort study of clinical outcomes after antiviral therapy for chronic hepatitis c

Conditions: Chronic Hepatitis C

Summary: this study was a clinical observational cohort study of two-way, non-intervention long-term dynamic follow-up. enrolled in the department of liver diseases, beijing ditan hospital, capital medical university, with interferon combined with ribavirin (pr) antiviral therapy (pr treatment greater than or equal to 6 months) and/or direct acting antivirals (daas) in patients with chronic hepatitis c, the baseline, antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected, and the patients were followed up for 3-6 months. clinical data such as clinical biochemistry, hcv rna and serological markers (anti-hcv), afp and liver imaging (liver ultrasound) were collected during the study period. at least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis c, the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment of patients long-term virological response and clinical outcomes, clarifying their influencing factors.

this study was a clinical observational cohort study of two-way, non-intervention long-term dynamic follow-up. enrolled in the department of liver diseases, beijing ditan hospital, capital medical university, with interferon combined with ribavirin (pr) antiviral therapy (pr treatment greater than or equal to 6 months) and/or direct acting antivirals (daas) in patients with chronic hepatitis c, the baseline, antiviral treatment and withdrawal follow-up data before the antiviral treatment were collected, and the patients were followed up for 3-6 months. clinical data such as clinical biochemistry, hcv rna and serological markers (anti-hcv), afp and liver imaging (liver ultrasound) were collected during the study period. at least 144 weeks of observation on the virological response and clinical outcome of anti-viral treatment of chronic hepatitis c, the main evaluation index of liver cancer and decompensated liver cirrhosis after stopping the drug, and exploring the antiviral treatment of patients long-term virological response and clinical outcomes, clarifying their influencing factors.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c patients treated with interferon plus ribavirin (pr) antiviral therapy (pr treatment greater than or equal to 6 months) and/or direct antiviral drugs (daas) exclusion criteria: * co-infected with hepatitis b virus or human immunodeficiency virus * had an autoimmune disease, liver tumour, or severe cardiac disease.

Keywords: chronic hepatitis c interferon ribavirin clinical outcome
qm-b and qm-c hysterectomy for early cervical cancer

Conditions: Uterine Cervical Neoplasms

Summary: the goal of this clinical research study is to compare the long-term outcomes and safety of querleu-morrow-b(qm-b) and querleu-morrow-c(qm-c) hysterectomy for early cervical cancer. in this study, the surgical approach for qm-b and qm-c hysterectomy will be abdominal.

primary objective: to compare 5-year overall survival and 5-year disease-free survival amongst patients who undergo a qm-b hysterectomy versus those who undergo a qm-c hysterectomy for early stage cervical cancer. secondary objectives: compare operation time between arms. compare blood loss between arms. compare blood transfusion between arms. compare intraoperative complications between arms. compare postoperative complications between arms. compare quality of lifes between arms.

Eligibility criteria:
inclusion criteria: * patients who have signed an approved informed consent * 18.5≤bmi\<28 * histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix; * patients with histologically confirmed stage ia1 (with lymph vascular invasion), stage ia2, stage ib1, stage ib2, or stage iia1 disease(figo 2018). * eastern cooperative oncology group(ecog) performance status of 0 or 1. * patients undergoing the non-fertility-sparing surgery. * patients undergoing abdominal surgery. exclusion criteria: * the life expectancy of the patient is less than 6 months. * patients with serious medical diseases. * patients with contraindications to surgery or anesthesia. * preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic lymph nodes. * patient asks to preserve fertility. * the patient requested direct radiation therapy. * patients with adjuvant radiotherapy or chemotherapy before surgery. * patients judged by the investigator to be unsuitable to participate in this trial.

Keywords: cervical cancer qm-b qm-c oncology outcome safety hysterectomy radical hysterectomy abdominal
examining effects of aerobic exercise on pain sensation

Conditions: Chronic Low Back Pain

Summary: by doing this study, researchers hope to learn effects of aerobic exercise on over activated nervous system in people with chronic low back pain.

chronic low back pain is a common condition in the world. about 85% of people with low back pain do not know the cause of their pain. this leads to ineffective treatments. recently, the idea of an over activated nervous system is thought to be one of the main reasons for chronic pain. over activated nervous system means pain processing areas in the spine or brain might be more sensitive. aerobic exercise, such as walking and cycling, is often used to decrease chronic pain. aerobic exercise is a form of physical exercise that strengthen the heart and lungs in order to improve the body's utilization of oxygen. the researchers want to examine if aerobic exercise is effective in decreasing over activation of the nervous system. gaining a better understanding of effects of aerobic exercise on the nervous system may lead to more effective treatments for low back pain.

Eligibility criteria:
inclusion criteria: * lower back pain (lbp) for more than 3 months * a minimal pain level of 3 on the 0-10 pain numerical rating scale (nrs) in the last 7 days * can read and understand english. exclusion criteria: * nerve root compression that resulted in numbness or decrease in sensation in the areas for the pain sensitivity tests as reported by the subject * cervical or thoracic pain as a main complaint * spinal pathologies such as fracture, tumor, infection, and severe inflammation * severe spinal deformity * severe cardiovascular and neurological diseases * cancer * history of spinal surgery * currently seeking active treatments for lbp other than medications * resting blood pressure more than 160/90 mmhg 49 * currently taking blood thinning medications * uncontrolled diabetes * cannot have blood pressure taken * participated in a similar trial in the past
psychosocial mobile application (thrive-m) for patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: this clinical trial aims to evaluate whether a psychosocial mobile application (thrive-m), is efficacious for improving quality of life, psychological distress, and fatigue in patients living with multiple myeloma compared to usual care.

multiple myeloma, the second most common hematologic malignancy, can be associated with severe end-organ destruction and life-threatening complications (e.g., kidney failure, infection, anemia) resulting in significant morbidity (e.g., pain syndromes, fatigue). the protracted course and treatment of multiple myeloma is also characterized by physical symptoms that can undermine psychological well-being, functioning, and quality of life across the illness trajectory and care continuum. despite the high psychological burden that may accompany life with multiple myeloma, the special mental health workforce needed to adequately address their psychological needs is limited. hence, mobile application-delivered psychosocial interventions offer an innovative approach to overcome the shortage of psychosocial services to support the unique needs of patients living with multiple myeloma. with no psychosocial mobile application interventions for patients living with multiple myeloma, we developed a patient-centered, population-specific, mobile-application psychosocial intervention, thrive-m, tailored to the unique needs of patients living with multiple myeloma. with this study, we will establish the impact of thrive-m on patient-reported outcomes compared to usual care. the study will use validated questionnaires to measure patients' quality of life, psychological distress symptoms, fatigue, and self-management targets like coping, spiritual well-being, and self-efficacy. study questionnaires will be completed in the hospital or clinic, with an option to also complete them remotely via a secure web link or a mailed paper copy. divine mercy university is funding this research study.

Eligibility criteria:
inclusion criteria: * adult patients (aged 18 years or older) with one of the following diagnoses: 1. newly diagnosed multiple myeloma receiving first-line therapy, 2. multiple myeloma on maintenance therapy, or 3. relapsed multiple myeloma receiving 2nd or 3rd line therapy * ability to comprehend, read, and respond to questions in english exclusion criteria: - patients with acute or unstable psychiatric or cognitive conditions that the treating clinicians believe prohibit informed consent or compliance with study procedures

Keywords: multiple myeloma
thrombolysis combined with edaravone dexborneol on hemorrhagic transformation for acute ischemic stroke

Conditions: Stroke, Ischemic

Summary: to explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received thrombolysis.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke; * 18 to 80 years of age; * there are clear signs of neurological deficit: 8≤nihss score≤24; * received alteplase thrombolysis therapy within 4.5 hours after onset; * patients signed written inform consent exclusion criteria: * patients need endovascular therapy or bridge therapy; * cranial ct scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage; * severe head trauma or stroke, intracranial tumor or large intracranial aneurysm within 3 months; * intracranial or intraspinal surgery within 3 months; * active visceral hemorrhage * major surgery within 2 weeks or arterial puncture within 1 week that is difficult to compress the hemostatic site; * unknown onset time; * rapid improvement of symptoms or mild symptoms before thrombolysis therapy; * a platelet count below 100,000/mm3 indicates a propensity for acute bleeding; * therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, urinary kallidinogenase; * patients with severe mental disorders and dementia; * alt or ast is greater than 2.0×uln or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis; * serum creatinine (scr) is greater than 1.5×uln, creatinine clearance (crcl) is less than 50 ml/min or previously known severe renal diseases; * patients with malignant tumors or severe systemic disease; * allergic to edaravone , (+)-borneol or related excipients; * pregnant or lactating women; * have major surgery within 4 weeks before enrollment; * participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present; * the investigators consider the patients are not suitable for this trial.
sublingual misoprostol for the treatment of incomplete abortion: operations research

Conditions: Incomplete Abortion

Summary: this study will investigate the use of misoprostol for first-line treatment of incomplete abortion at tertiary hospitals in myanmar.

this open-label feasibility study seeks to examine the potential of 400μg sublingual misoprostol for the treatment of incomplete abortion provided at tertiary hospitals.

Eligibility criteria:
inclusion criteria: 1. confirmed incomplete abortion 2. no known contraindications to the study drug 3. uterine size no larger than 12 weeks at time of presentation for care 4. no signs of severe infection, defined as at least two of the following: * foul smelling discharge, * fever \> 38 degrees c, 100 degrees fahrenheit * uterine tenderness. 5. no hemodynamic disturbances (pulse \>110/min and systolic bp \<100) 6. general good health 7. agree to comply with study procedures including return for follow up visit 8. live or work within one hour from a study site 9. willing and able to sign consent forms exclusion criteria: 1. inability to provide informed consent
early detection of deafness in a memory center

Conditions: Cognitive Disorder; Deafness

Summary: age-related hearing loss (arhl), like neurodegenerative diseases, appears insidiously with age. as major public health issues, they are nonetheless under-diagnosed because the presence of one can hinder the objectification of the other. the cogaudio project aims to detect early and in an ambulatory mode in a memory centre a speech perception disorder in noise thanks to the vrb test in patients weakened by cognitive disorders.


Eligibility criteria:
inclusion criteria: * patient with mild to moderate cognitive impairment, with an mmse score ≥15/30 * patient mastering the french language * patient who has given written consent to participate in the trial * socially insured patient * patient willing to comply with all study procedures and duration * patient accompanied by a study partner exclusion criteria: * medical history of diagnosed deafness, fitted or not * history of progressive otological pathology or presence of tympanic obstruction (\>1/3 of the surface of the eardrum) * history of unstabilized psychiatric pathology * major visual impairment (age-related macular degeneration amd...) * established diagnosis of major language disorders (primary progressive aphasia app...) * major under legal protection measure

Keywords: cognitive disorder deafness
circadian phase adjustment and improvement of metabolic control in night shift workers

Conditions: Sleep Disorders, Circadian Rhythm

Summary: eurhythdia ii is a multicenter, randomized, double-blind controlled study. the rationale of eurhythdia is to explore the effects of 12 weeks of timed melatonin treatment on circadian rhythm, metabolic control and cardiovascular function in night shift workers. the 12 weeks of intervention will be followed by 12 weeks of washing out.

modern lifestyle has dramatically changed the daily rhythms of life. physical activity, diet and light exposure are no longer restricted to daytime hours due to increased shift work. recent scientific reports have shown that shift work leads to disruption of circadian rhythms and promotes diabetes, obesity and cardiovascular disease. until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes and obesity have been conducted in man. thus, knowledge of the molecular pathways and the responsibles genes in man are missing and have been identified only in animal studies. the objective of the project is to achieve breakthroughs in the understanding of the causality between inner clock rhythm disturbances and the development of type 2 diabetes and obesity. the provided data on the interaction between genes, epigenetics, metabolism, cardiovascular function and the internal clock are intended to contribute to identify novel biomarkers and novel therapeutic approaches focusing on circadian rhythms to reduce the occurence of diabetes and obesity in shift worker.

Eligibility criteria:
inclusion criteria: * male and female above the age of 18 * night shift workers on regular night shifts (at least 6 months before inclusion into the study and at least 4 night shifts per month during the study period exclusion criteria: * pregnancy or breast feeding * known autoimmune disease * current or relevant history of physical or psychiatric illness * evidence of renal insufficiency or liver disease * known or suspected intolerance or hypersensitivity to the study medication * use of certain drugs within 4 weeks prior to the inclusion to the study

Keywords: type 2 diabetes metabolic control metabolomics circadian rhythm melatonin biomarker clock gene pbmc cardiovascular function epigenetic modification lifestyle intervention